Provided by Tiger Trade Technology Pte. Ltd.

Relmada Therapeutics, Inc.

3.54
-0.1800-4.84%
Volume:235.48K
Turnover:831.06K
Market Cap:259.60M
PE:-2.00
High:3.73
Open:3.72
Low:3.45
Close:3.72
52wk High:5.12
52wk Low:0.2404
Shares:73.33M
Float Shares:63.15M
Volume Ratio:0.74
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7693
EPS(LYR):-2.6515
ROE:-196.79%
ROA:-102.41%
PB:27.43
PE(LYR):-1.34

Loading ...

Relmada Therapeutics Inc : Leerink Partners Raises to Outperform From Market Perform; Raises Target Price to $8 From $1

THOMSON REUTERS
·
Jan 23

Relmada Therapeutics provides regulatory update on FDA alignment for NDV-01

TIPRANKS
·
Jan 12

Relmada Therapeutics Inc - FDA Supports Randomized Trial for Ndv-01 in Intermediate-Risk Nmibc

THOMSON REUTERS
·
Jan 12

Relmada Therapeutics Inc - Receives FDA Feedback on Ndv-01 Studies

THOMSON REUTERS
·
Jan 12

Relmada Therapeutics Inc - FDA Supports Single-Arm Trial for Ndv-01 in High-Grade Nmibc

THOMSON REUTERS
·
Jan 12

Relmada Therapeutics Inc - to Start Registrational Trials in 1H 2026

THOMSON REUTERS
·
Jan 12

Relmada Therapeutics Inc : Jefferies Initiates Coverage With Buy Rating; Target Price $9

THOMSON REUTERS
·
Dec 22, 2025

Relmada Therapeutics CFO Maged Shenouda Reports Acquisition of Common Shares

Reuters
·
Dec 16, 2025

Relmada Therapeutics Raises Executive Salaries in Amended Employment Agreements

Reuters
·
Dec 15, 2025

Mizuho Securities upgrades Relmada Therapeutics (RLMD) to a Buy

TIPRANKS
·
Nov 19, 2025

Relmada Therapeutics Inc : Mizuho Raises to Outperform From Neutral; Raises Target Price to $10 From $1

THOMSON REUTERS
·
Nov 19, 2025

Relmada Therapeutics CAO and COO Chuck Ence Acquires Common Shares

Reuters
·
Nov 06, 2025

Relmada Therapeutics CFO Maged Shenouda Reports Acquisition of Common Shares

Reuters
·
Nov 06, 2025

Relmada Therapeutics announces FDA feedback on study paths for NDV-01

TIPRANKS
·
Nov 04, 2025

Relmada Therapeutics prices 40.1M shares at $2.20 in underwritten offering

TIPRANKS
·
Nov 04, 2025

BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer

Reuters
·
Nov 04, 2025

Relmada Therapeutics Inc: Common Stock Are Being Sold at an Offering Price of $2.20 per Share

THOMSON REUTERS
·
Nov 04, 2025

Relmada Therapeutics Inc - Secures FDA Alignment for Phase 3 Ndv-01 Program

THOMSON REUTERS
·
Nov 04, 2025

Relmada Therapeutics Inc - FDA Confirms No Additional Non-Clinical Studies Required for Ndv-01

THOMSON REUTERS
·
Nov 04, 2025

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for Ndv-01 in Non-Muscle Invasive Bladder Cancer

THOMSON REUTERS
·
Nov 04, 2025